Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis

World Journal of Gastroenterology

Volumn 21, Issue 10, 2015, Pages 3020-3029

  Kalafateli, Maria ^a   Triantos, Christos ^a   Tsochatzis, Emmanuel ^b   Michalaki, Marina ^a   Koutroumpakis, Efstratios ^a   Thomopoulos, Konstantinos ^a   Kyriazopoulou, Venetsanea ^a   Jelastopulu, Eleni ^c   Burroughs, Andrew ^b   Lambropoulou Karatza, Chryssoula ^a   Nikolopoulou, Vasiliki ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

Adipokines; Adiponectin; Cirrhosis; Leptin; Resistin

Indexed keywords

ADIPONECTIN; APELIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; RETINOL BINDING PROTEIN 4; ADIPOCYTOKINE; BIOLOGICAL MARKER;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BODY MASS; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT MASS; FEMALE; FOLLOW UP; HUMAN; IMPEDANCE; LIVER CIRRHOSIS; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; OVERALL SURVIVAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TOTAL BODY WATER; AGED; BLOOD; CHI SQUARE DISTRIBUTION; DISEASE COURSE; LIVER CIRRHOSIS, ALCOHOLIC; LIVER FUNCTION TEST; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; OBESITY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADIPOKINES; ADIPOSITY; ADULT; AGED; BIOMARKERS; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; ELECTRIC IMPEDANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84925016419     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i10.3020     Document Type: Article

References (53)

1. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006; 101: 2629-2640 [PMID: 16952281 DOI: 10.1111/j.1572-0241.2006.00848.x]
2. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887 [PMID: 17167477 DOI: 10.1038/nature05488]
3. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383: 1749-1761 [PMID: 24480518 DOI: 10.1016/S0140-6736(14)60121-5]
4. Tsochatzis E, Papatheodoridis GV, Hadziyannis E, Georgiou A, Kafiri G, Tiniakos DG, Manesis EK, Archimandritis AJ. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008; 43: 1128-1136 [PMID: 18609175 DOI: 10.1080/00365520802085387]
5. Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis 2007; 11: 173-189, x [PMID: 17544978 DOI: 10.1016/j.cld.2007.02.007]
6. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010; 59: 1410-1415 [PMID: 20660697 DOI: 10.1136/gut.2010.213553]
7. Diehl AM. Obesity and alcoholic liver disease. Alcohol 2004; 34: 81-87 [PMID: 15670669 DOI: 10.1016/j.alcohol.2004.07.010]
8. Marra F, Navari N, Vivoli E, Galastri S, Provenzano A. Modulation of liver fibrosis by adipokines. Dig Dis 2011; 29: 371-376 [PMID: 21894007 DOI: 10.1159/000329799]
9. Novo E, Cannito S, Paternostro C, Bocca C, Miglietta A, Parola M. Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys 2014; 548: 20-37 [PMID: 24631571 DOI: 10.1016/j.abb.2014.02.015]
10. Honda H, Ikejima K, Hirose M, Yoshikawa M, Lang T, Enomoto N, Kitamura T, Takei Y, Sato N. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002; 36: 12-21 [PMID: 12085344 DOI: 10.1053/jhep.2002.33684]
11. Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002; 122: 1399-1410 [PMID: 11984526 DOI: 10.1053/gast.2002.32995]
12. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37: 206-213 [PMID: 12127425 DOI: 10.1016/S0168-8278(02)00102-2]
13. Zhang W, Niu M, Yan K, Zhai X, Zhou Q, Zhang L, Zhou Y. Stat3 pathway correlates with the roles of leptin in mouse liver fibrosis and sterol regulatory element binding protein-1c expression of rat hepatic stellate cells. Int J Biochem Cell Biol 2013; 45: 736-744 [PMID: 23295202 DOI: 10.1016/j.biocel.2012.12.019]
14. McCullough AJ, Bugianesi E, Marchesini G, Kalhan SC. Gender-dependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology 1998; 115: 947-953 [PMID: 9753498 DOI: 10.1016/S0016-5085(98)70267-7]
15. Testa R, Franceschini R, Giannini E, Cataldi A, Botta F, Fasoli A, Tenerelli P, Rolandi E, Barreca T. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J Hepatol 2000; 33: 33-37 [PMID: 10905583 DOI: 10.1016/S0168-8278(00)80156-7]
16. Henriksen JH, Holst JJ, Møller S, Brinch K, Bendtsen F. Increased circulating leptin in alcoholic cirrhosis: relation to release and disposal. Hepatology 1999; 29: 1818-1824 [PMID: 10347125 DOI: 10.1002/hep.510290601]
17. Bolukbas FF, Bolukbas C, Horoz M, Gumus M, Erdogan M, Zeyrek F, Yayla A, Ovunc O. Child-Pugh classification dependent alterations in serum leptin levels among cirrhotic patients: a case controlled study. BMC Gastroenterol 2004; 4: 23 [PMID: 15387890 DOI: 10.1186/1471-230X-4-23]
18. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, Deveci MS, Bagci S, Gulsen M, Karaeren N, Dagalp K. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95: 3584-3589 [PMID: 11151896 DOI: 10.1111/j.1572-0241.2000.03297.x]
19. Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, Giudicelli J, Ferrua B, Laffont C, Benzaken S, Tran A. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 2004; 11: 91-96 [PMID: 14738564 DOI: 10.1046/j.1365-2893.2003.00483.x]
20. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, Considine RV. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 2003; 98: 2771-2776 [PMID: 14687831 DOI: 10.1111/j.1572-0241.2003.08767.x]
21. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41: 943-949 [PMID: 15582127 DOI: 10.1016/j.jhep.2004.08.020]
22. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, Jonsson JR. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003; 39: 1042-1048 [PMID: 14642624 DOI: 10.1016/S0168-8278(03)00463-X]
23. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochem Biophys Res Commun 2012; 425: 560-564 [PMID: 22925674 DOI: 10.1016/j.bbrc.2012.08.024]
24. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100 [PMID: 12840063 DOI: 10.1172/JCI200317797]
25. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T, Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-1807 [PMID: 14724832 DOI: 10.1053/j.gastro.2003.08.029]
26. Buechler C, Schäffler A, Johann M, Neumeier M, Köhl P, Weiss T, Wodarz N, Kiefer P, Hellerbrand C. Elevated adiponectin serum levels in patients with chronic alcohol abuse rapidly decline during alcohol withdrawal. J Gastroenterol Hepatol 2009; 24: 558-563 [PMID: 19067777 DOI: 10.1111/j.1440-1746.2008.05693.x]
27. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312 [PMID: 11201732 DOI: 10.1038/35053000]
28. Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW, Scherer PE, Rossetti L. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004; 114: 232-239 [PMID: 15254590 DOI: 10.1172/JCI200421270]
29. Dong ZX, Su L, Brymora J, Bird C, Xie Q, George J, Wang JH. Resistin mediates the hepatic stellate cell phenotype. World J Gastroenterol 2013; 19: 4475-4485 [PMID: 23901222 DOI: 10.3748/wjg.v19.i28.4475]
30. Bahr MJ, Ockenga J, Böker KH, Manns MP, Tietge UJ. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance. Am J Physiol Endocrinol Metab 2006; 291: E199-E206 [PMID: 16478779 DOI: 10.1152/ajpendo.00291.2005]
31. Kakizaki S, Sohara N, Yamazaki Y, Horiguchi N, Kanda D, Kabeya K, Katakai K, Sato K, Takagi H, Mori M. Elevated plasma resistin concentrations in patients with liver cirrhosis. J Gastroenterol Hepatol 2008; 23: 73-77 [PMID: 18171344]
32. Yagmur E, Trautwein C, Gressner AM, Tacke F. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 2006; 101: 1244-1252 [PMID: 16771945 DOI: 10.1111/j.1572-0241.2006.00543.x]
33. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008; 14: 741-751 [PMID: 19009016 DOI: 10.2119/2008-00058.Rabe]
34. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-2563 [PMID: 16775236 DOI: 10.1056/NEJMoa054862]
35. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, Fritsche A, Häring HU. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 2007; 30: 1173-1178 [PMID: 17259477 DOI: 10.2337/dc06-2342]
36. Bełtowski J. Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity? Med Sci Monit 2006; 12: RA112-RA119 [PMID: 16733497]
37. Principe A, Melgar-Lesmes P, Fernández-Varo G, del Arbol LR, Ros J, Morales-Ruiz M, Bernardi M, Arroyo V, Jiménez W. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology 2008; 48: 1193-1201 [PMID: 18816630 DOI: 10.1002/hep.22467]
38. Kuczmarski RJ, Flegal KM. Criteria for definition of overweight in transition: background and recommendations for the United States. Am J Clin Nutr 2000; 72: 1074-1081 [PMID: 11063431]
39. Tietge UJ, Bahr MJ, Manns MP, Böker KH. Altered alanine plasma levels despite normalized hepatic alanine extraction in the long-term course after liver transplantation. Transplantation 2003; 75: 804-810 [PMID: 12660506 DOI: 10.1097/01.TP.0000054843.68371.AA]
40. Pirlich M, Schütz T, Spachos T, Ertl S, Weiss ML, Lochs H, Plauth M. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology 2000; 32: 1208-1215 [PMID: 11093726 DOI: 10.1053/jhep.2000.20524]
41. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74 [PMID: 20175034 DOI: 10.1055/s-0030-1247133]
42. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008; 70: 537-556 [PMID: 17937601 DOI: 10.1146/annurev.physiol.70.113006.100707]
43. Campillo B, Sherman E, Richardet JP, Bories PN. Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism. Eur J Clin Nutr 2001; 55: 980-988 [PMID: 11641747 DOI: 10.1038/sj.ejcn.1601255]
44. Tietge UJ, Böker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287: E82-E89 [PMID: 15010338 DOI: 10.1152/ajpendo.00494.2003]
45. van der Poorten D, Samer CF, Ramezani-Moghadam M, Coulter S, Kacevska M, Schrijnders D, Wu LE, McLeod D, Bugianesi E, Komuta M, Roskams T, Liddle C, Hebbard L, George J. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology 2013; 57: 2180-2188 [PMID: 22996622 DOI: 10.1002/hep.26072]
46. Kaser S, Moschen A, Kaser A, Ludwiczek O, Ebenbichler CF, Vogel W, Jaschke W, Patsch JR, Tilg H. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 2005; 258: 274-280 [PMID: 16115302 DOI: 10.1111/j.1365-2796.2005.01543.x]
47. Tacke F, Wüstefeld T, Horn R, Luedde T, Srinivas Rao A, Manns MP, Trautwein C, Brabant G. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol 2005; 42: 666-673 [PMID: 15826715 DOI: 10.1016/j.jhep.2004.12.024]
48. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly S. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199-2202 [PMID: 11574398 DOI: 10.2337/diabetes.50.10.2199]
49. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472-476 [PMID: 12504108 DOI: 10.1016/S0006-291X(02)02841-3]
50. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004; 1: e45 [PMID: 15578112 DOI: 10.1371/journal.pmed.0010045]
51. Filippatos TD, Derdemezis CS, Kiortsis DN, Tselepis AD, Elisaf MS. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007; 30: 323-326 [PMID: 17556870 DOI: 10.1007/BF03346300]
52. de Boer JF, Bahr MJ, Böker KH, Manns MP, Tietge UJ. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G196-G201 [PMID: 19074645 DOI: 10.1152/ajpgi.00029.2008]
53. Yagmur E, Weiskirchen R, Gressner AM, Trautwein C, Tacke F. Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. Diabetes Care 2007; 30: 1168-1172 [PMID: 17337499 DOI: 10.2337/dc06-2323]